Antineoplastic - Protein-Tyrosine Kinase Inhibitors

Antineoplastic protein-tyrosine kinase inhibitors are a targeted therapeutic class of predominantly small-molecule agents designed to treat diverse malignancies Clinically, these agents play a foundational role in managing both hematologic neoplasms, such as chronic myeloid leukemia, and a broad range of solid tumors, including non-small cell lung cancer, renal cell carcinoma, gastrointestinal stromal tumors, and breast cancer

Antineoplastic protein-tyrosine kinase inhibitors are a targeted therapeutic class of predominantly small-molecule agents designed to treat diverse malignancies They function by competitively inhibiting the adenosine triphosphate (ATP)–binding sites or allosteric regulatory domains of receptor and non-receptor tyrosine kinases, thereby disrupting downstream intracellular signaling cascades essential for oncogenic cell proliferation, survival, and angiogenesis

They function by competitively inhibiting the adenosine triphosphate (ATP)–binding sites or allosteric regulatory domains of receptor and non-receptor tyrosine kinases, thereby disrupting downstream intracellular signaling cascades essential for oncogenic cell proliferation, survival, and angiogenesis

Clinically, these agents play a foundational role in managing both hematologic neoplasms, such as chronic myeloid leukemia, and a broad range of solid tumors, including non-small cell lung cancer, renal cell carcinoma, gastrointestinal stromal tumors, and breast cancer